Endospan Acquired by Artivion After FDA Approval of NEXUS Aortic Arch System
Endospan has been acquired by Artivion, Inc. following the FDA PMA approval of its NEXUS® Aortic Arch System. This system is the first off-the-shelf endovascular solution aimed at treating aortic arch disease, particularly for patients at high risk.
HERZLIYA, Israel–(BUSINESS WIRE)– #aortaEd–Endospan, a pioneer in endovascular solutions for complex aortic pathologies, today announced that Artivion, Inc. (NYSE: AORT) has closed the transaction to acquire the company. This strategic milestone follows the April 2026 U.S. Food and Drug Administration (FDA) PMA approval of the NEXUS® Aortic Arch System, the first off-the-shelf endovascular solution designed to treat aortic arch disease, including chronic aortic dissections, in patients at high risk for